CCR2 and Patent ductus arteriosus: Consistent with these findings, focused inhibition of CCR2 with a novel inhibitor renders primary and metastatic PDA tumors susceptible to ICB, a behavior that is augmented, in part, through increased antitumor immunity from elevated levels of IL-33 in cancer cells.